Statistics from Altmetric.com
We thank Iacopetta and Watanabe for their interest in our paper (Gut 2006;55:1671–2). We do not agree, however, with their conclusions. There is important evidence in the recent literature that supports a relative lack of efficacy for 5-fluorouracil (5-FU) in patients with mismatch repair (MMR)-deficient tumours, with several studies reaching similar conclusions.1–4 In our study, we did not find major differences in patients with MMR-deficient tumours in survival or disease-free survival regarding adjuvant treatment, especially when we compared those results with the ones obtained in patients with MMR-proficient tumours. Although we acknowledge that we had only 53 patients with MMR-deficient tumours, our …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.